



JFW

1647
#

PATENT
ATTORNEY DOCKET NO. 54458-20002.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--|---|----------------------------------|
| In re Application of: |) | |
| |) | |
| Anton WELLSTEIN |) | Group Art Unit: 1647 |
| |) | |
| Application Number: 09/880,097 |) | Examiner: Nichols, Christopher J |
| |) | |
| Filed: June 14, 2001 |) | |
| |) | |
| Title: PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS |) | |

Commissioner of Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicant is submitting herewith copies of the references listed on the attached Form PTO-1449 for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed PTO Form-1449 with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested. In addition, enclosed is a copy of the International Search Report dated November 28, 2002.

This Information Disclosure Statement is being submitted after receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this

07/21/2004 CCHAU1 00000154 031952 09880097

01 FC:1806 180.00 DA

submission in duplicate. However, in the event any additional fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 03-1952.

Respectfully submitted,

MORRISON & FOERSTER LLP

Dated: July 20, 2004

By: 

James Remenick
Registration No. 36,902

Customer Number 25227
Morrison & Foerster LLP
1650 Tyson's Boulevard
Suite 300
McLean, Virginia 22102
(703) 760-7700 (telephone)
(703) 760-7777 (facsimile)

Form PTO-1449

Docket Number: 544582000200

Application Number (serialno)

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Applicant

Anton WELLSTEIN

Filing Date: June 14, 2001

Group Art Unit: 1647

Mailing Date: July 14, 2004



U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|----------|------------|--------------|---------------|-------|----------|----------------------------|
| | 1. | 06/23/1998 | 5,770,421 | Morris et al. | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Country | Class | Subclass | Translation YES NO | |
|-------------------|----------|------------|--------------|---------|-------|----------|-----------------------|--|
| | 2. | 04/13/2000 | 00/20869 | WIPO | | | x | |
| | 3. | | | | | | | |

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

| Examiner Initials | Ref. No. | Title |
|-------------------|----------|---|
| | 4. | Kung Meng et al., (Pleiotrophin signals increased tyrosine phosphorylation of b-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase B/ζ) March 14, 2000, Vol. 97 no 6 pp. 2603-2608 |
| | 5. | Nobuaki Maeda et al., (A Receptor-like Protein-tyrosine Phosphatase PTP/RPTPB Binds a Heparin-binding Growth Factor Midkine) Vol. 274, No. 18. Issue of April 33, pp. 12474-12479. |
| | 6. | Nobuaki Maeda et al., (6B4 Proteoglycan/Phosphacan, an Extracellular Variant of Receptor-like Protein-tyrosine Phosphatase RPTPB, Binds Pleiotrophin/Heparin-binding Growth-associated Molecule (HB-GAM)* Vol. 271, No. 35, Issue of August 30, pp. 21446-21452 |
| | 7. | Erkki Raulo et al., (Isolation of a Neuronal Cell Surface Receptor of Heparin Binding Growth-associated Molecule (HB-GAM) Vol. 269, No. 17, Issue of April 29, pp. 12999-13004 |
| | 8. | K. Matsumoto et al., (A novel family of heparin-binding growth factors, pleiotrophin and midkine, is expressed in the developing rat cerebral cortex) Developmental Brain Research 79 (1994) 229-241 |
| | 9. | Nan Zhang et al., (Domain Structure of Pleiotrophin Required for Transformation) Vol. 274, No. 19, Issue of May 7, pp. 12959-12962 |
| | 10. | Dorothy J. Caughey et al., (Fractionation of polyclonal antibodies to fragments of a neuroreceptor using three increasingly chaotropic solvents) Journal of Chromatography B, 728 (1999) 49-57 |
| | 11. | Stephan W. Morris et al., (ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neutral receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene (1997) 14, 2175-2188 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number: 544582000200

Application Number (serialno)

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)


Applicant

Anton WELLSTEIN

Filing Date: June 14, 2001

Group Art Unit: 1647

Mailing Date: July 14, 2004



| | |
|-----|---|
| 12. | Toshinori Iwahara et al., (Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system) <i>Oncogene</i> (1997) 14, 439-449 |
| 13. | Karen Pulford et al., (Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM) – ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1) <i>Blood</i> , Vol. No. 4, February 15, 1997: pp. 1394-1404 |
| 14. | A. Aigner, et al., (Identification of a Receptor for the Growth Factor Pleiotrophin, its Signal Transduction and Potential Role in Cancer) <i>Proceedings of AACR</i> ; Vol. 40, p. 732; March 1999. |
| 15. | Gerald E. Stoica et al., (Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin) <i>Vol. 276, No. 20, Issue of May 18, pp. 16772-16779</i> |
| 16. | James A. Wells, (Additivity of Mutational Effects of Proteins), <i>Biochemistry</i> Vol. 29, No. 37, September 18, 1990 |
| 17. | Nobuaki Maeda et al., (A Receptor-like Protein-tyrosine Phosphatase PTP/RPTP B Binds a Herparin-binding Growth Factor Midkine) <i>Vol. 274, No. 18, Issue of April 30, pp. 12474-12479</i> |
| 18. | Temple F. Smith et al., (The challenges of genome sequence annotation or “The devil is in the details”) <i>Nature Biotechnology</i> Volume 15, November 1997 |
| 19. | Jeffrey Skolnick et al., (From genes to protein structure and function: novel applications of computational approaches in the genomic era) <i>Tibtech</i> January 2000, Vol. 18, pp 34-39. |
| 20. | Genetwork (Go hunting in sequence database but watch out for the traps) <i>TIG</i> October 1996, Vol. 12, No. 10, pp. 425-427 |
| 21. | Peer Bork (Powers and Pitfalls in Sequence Analysis: The 70% Hurdle) <i>Cold Spring Harbor Laboratory Press</i> (2000) pp. 398-400 |
| 22. | Kung Meng., (Pleiotrophin signals increased tyrosine phosphorylation of B-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase B/ζ) <i>PNAS</i> , March 14, 2000, Vol. 97, No. 6, pp. 2603-2608 |
| 23. | Gerald E. Stoica., (Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*), <i>Journal of Biological Chemistry</i> , Vol. 276, No. 20, Issue of May 18, pp: 16772-16779 |
| 24. | Kenneith M. Merz, Jr. et al., (The Protein Folding Problem and Tertiary Structure Prediction) <i>Birkhäuser Boston</i> 1994, Ch 14, pp. 433-506. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.